NEW YORK--(BUSINESS WIRE)--
Bragar Eagel & Squire, P.C. is investigating potential claims against MiMedx Group, Inc. (NASDAQ:MDXG). Our investigation concerns whether MiMedx Group has violated the federal securities laws and/or engaged in other unlawful business practices.
On September 20, 2017, the market research groups Aurelius Value and Viceroy Research published reports alleging that MiMedx may be under investigation by the SEC. The Aurelius report claimed to “see large undiscounted channel stuffing and kickback risks lurking beneath the surface at MiMedx,” while the Viceroy report similarly stated that “a number of former employees-turned whistleblowers have accused MiMedx of aggressive channel-stuffing practices and improper revenue recognition policies.” Following this news, shares of MiMedx fell $0.82, or 6.2%, to close at $12.34 on September 20, 2017.
On September 21, 2017, MiMedx issued a press release acknowledging it was working with the SEC in its investigation.
If you purchased or otherwise acquired MiMedx securities and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into MiMedx Group, please go to http://www.bespc.com/mdxg. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006456/en/
